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Transplantation of hematopoietic stem cells (HSCs) from human umbilical cord blood (hUCB) 
holds great promise for treating a broad spectrum of hematological disorders including cancer, 
but the limited number of HSCs in a single hUCB unit restricts its widespread use. Although 
extensive efforts have developed multiple methods for ex vivo expansion of human HSCs by 
targeting single molecules or pathways, it remains unknown whether simultaneously 
manipulating a large number of targets essential for stem cell self-renewal could be achievable. 
Recent studies have emerged that N6-methyladenosine (m6A) modulates expression of a group of 
mRNAs critical for stem cell fate determination by influencing their stability. Among several 
m6A readers, Ythdf2 is well recognized to promote the targeted mRNA decay.  However, the 
physiological functions of Ythdf2 on adult stem cells are still elusive. Here we show that 
conditional knockout (KO) mouse Ythdf2 increased phenotypic and functional HSC numbers, 
but neither skewed lineage differentiation nor led to hematopoietic malignancies. Furthermore, 
knockdown (KD) of human YTHDF2 led to over 10-fold increase in ex vivo expansion of hUCB 
HSCs, 5-fold increase in colony-forming units (CFUs), and more than 8-fold increase in 
functional hUCB HSCs in the secondary serial of limiting dilution transplantation assay. 
Mechanistically, m6A mapping of RNAs from mouse hematopoietic stem and progenitor cells 
(HSPCs) as well as from hUCB HSCs revealed m6A enrichment on mRNAs encoding 
transcription factors critical for stem cell self-renewal. These m6A-marked mRNAs were 
recognized by Ythdf2 and underwent mRNA decay. In Ythdf2 KO HSPCs and YTHDF2 KD 
hUCB HSCs, these mRNAs were stabilized, leading to an increase in protein levels and 
facilitating HSC expansion. Knockdown one of the Ythdf2 key targets, Tal1 mRNA, partially 
rescued the phenotype. Therefore, our study for the first time shows the function of Ythdf2 in 
adult stem cell maintenance and identifies an important role of Ythdf2 in regulating HSC ex vivo 
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expansion via the mechanism of controlling the stability of multiple mRNAs critical for HSC 
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Chapter 1 : Introduction 
The origin of the term Stammzelle “German for stem cell” which was first used to 
describe the unicellular ancestor of all multicellular organisms and the fertilized egg that gives 
rise to all cells of the organism, can be traced back to 1868 in the works of German biologist 
Ernst Haeckel (Ramalho-Santos & Willenbring, 2007). Even over a century after the existence of 
the stem cell was proposed, the studies of the development and function of stem cells still attract 
tremendous efforts of both biologists and clinicians, holding a brilliant potential for clinical 
applications, such as disease modeling, drug screening and stem cell therapy (Wu & Izpisua 
Belmonte, 2016).  
Stem cells are a population of cells with remarkable ability to replenish themselves 
through self-renewal and to give rise to downstream differentiated cell lineages (Y. C. Hsu & 
Fuchs, 2012; Li & Clevers, 2010). The regulation of stem cells is essential to support embryo 
development and organ formation as well as maintenance of tissue homeostasis. The disruption 
of stem cell regulation is strongly linked with aging and diseases such as defects in tissue 
functions and cancer (Hanahan & Weinberg, 2011; Lopez-Otin, Blasco, Partridge, Serrano, & 
Kroemer, 2013; Shlush et al., 2014).   
1.1      Hematopoietic stem cell 
Hematopoiesis is one of the pioneering field that proposed and adapted the concept of 
“stem cell” to explain the diversity of blood lineages as early as 1908 (Ramalho-Santos & 
Willenbring, 2007). Over 50 years later, the definitive evidence was first provided by James Till 
and Ernest McCulloch, showing the regenerative potential of hematopoietic stem cells (HSCs) 
with clonal in vivo repopulation assays, thus establishing the existence of multipotential HSCs 
(Till & Mc, 1961).  
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HSCs, one of the best characterized stem cells, are defined by their capacity to give rise 
to all the blood cell types (Weissman, 2000). The lineage and self-renewal potential of HSCs can 
be determined by long-term repopulating assays, the most common of which is the competitive 
repopulation assay. This assay measures the functional potential of the experimental HSCs 
against a set known number of HSCs (usually from the bone marrow of congenic wild type 
mice), providing the qualitative or at best semiquantitative information about the experimental 
HSCs. It is important to note that this method is limited in the ability to distinguish between the 
number of HSCs or the quality of individual HSCs (Purton & Scadden, 2007). HSCs can also be 
defined on the immunophenotypic level. Combined with the usage of a wide array of cell surface 
antibodies and flow sorting, at least two populations of HSCs can be isolated: long-term (LT-) 
HSCs with quiescence (characterized by high percentage of cells in G0 phase) and highest self-
renewal capacity that function over 16-44 weeks when transplanted into mice; and short-term 
(ST-) HSCs that enrich actively cycling HSCs and sustain hematopoiesis for around 4-6 weeks 
(Wilson et al., 2008).  
1.1.1    HSCs in development 
There are multiple waves of hematopoiesis during development. The initial wave of  
blood production, known as “primitive hematopoiesis”, happens in the mammalian yolk sac at 
7.5-day and 21-day post fertilization in mouse and human, respectively (Figure 1.1). The primary 
function of primitive hematopoiesis is to produce red blood cells in order to fulfill the high 
requirement of oxygen during embryo rapid growth. Interestingly, the emergence of multipotent 
HSCs occurs after primitive hematopoiesis at the aorta-gonad mesonephros (AGM) region 
during embryonic day 10.5 (E10.5) and E28 in mouse and human, respectively. The primitive 
hematopoiesis is rapidly replaced by HSC-derived blood production that is termed “definitive” 
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(Orkin & Zon, 2008; Rowe, Mandelbaum, Zon, & Daley, 2016). It has been shown that HSCs de 
novo arise from endothelial cells in AGM via the endothelial-to-hematopoietic transition (EHT) 
(Muller, Medvinsky, Strouboulis, Grosveld, & Dzierzak, 1994). After E12.5, mouse definitive 
HSCs migrate to fetal liver and placenta where HSCs undergo expansion and reach a peak at 
E16.5. Around E17.5, fetal HSCs seed to bone marrow (BM) and home in an microenvironment 
or niche during the rest of life time (Mikkola & Orkin, 2006).  
 
Figure 1.1 Timeline of hematopoietic system development across species. 
The development of hematopoiesis during embryonic stages at specific anatomic sites in human 





1.1.2    HSC niches in bone marrow 
HSCs have been shown to reside in microenvironment or niches in the bone marrow 
where a complex milieu of components is responsible for the balance of HSC maintenance and 
differentiation, including soluble cytokines, intrinsic signaling pathways as well as physical and 
chemical signals from microenvironment, such as those mediated by adhesion molecules, local 
oxygen tension, temperature and shear forces (Mendelson & Frenette, 2014; L. D. Wang & 
Wagers, 2011; Xie & Li, 2007). Linheng Li’s Laboratory together with David Scadden’s 
laboratory first reported that phenotypic HSCs can be found adjacent to osteoblasts or N-Cad+ 
cells on the inner surface of trabecular bone, and subsequent genetic studies have further shown 
that expansion of trabecular bone, leads to expansion of HSCs (Calvi et al., 2003; J. Zhang et al., 
2003). These data provided the first evidence of specific heterologous cells regulating 
mammalian adult stem cells in vivo. In line with this, later studies showed that disruption of 
endosteal niche results in the development of myeloid disorders (Kode et al., 2014; Raaijmakers 
et al., 2010). 
 Following the initial study of N-cad+ cells in the endosteal region, other cell types have 
been suggested to regulate HSC maintenance and regeneration, such as perivascular cells and 
endothelial cells. For example, perivascular stromal cells expressing high levels of 
CXCL12, known as CXCL12-abundant reticular (CAR) cells, are involved in the regulation of 
HSC functionality in several aspects, including self-renewal, proliferation and trafficking 
(Sugiyama, Kohara, Noda, & Nagasawa, 2006). Recent studies show that mesenchymal stem 
cells (MSCs), which possess the capacity to give rise to osteoblasts, adipocytes, and 
chondroblasts, have considerable influence on HSC maintenance in vivo by expressing SCF or 
CXCL12 (Ding & Morrison, 2013; Mendez-Ferrer et al., 2010; B. O. Zhou, Yue, Murphy, Peyer, 
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& Morrison, 2014). In addition to the mesenchymal cells, terminally differentiated progeny of 
HSCs, including megakaryocytes and macrophages, have also been documented to regulate HSC 
activity directly (Bruns et al., 2014; Chow et al., 2011; Christopher, Rao, Liu, Woloszynek, & 
Link, 2011; M. Zhao et al., 2014). Previous studies have focused on a population of HSCs 
identified by signaling lymphocyte activation molecule family markers (SLAM family markers) 
and show their interactions and relative physical distance to niche cells. However, accumulated 
evidence reveals a tremendous molecular and functional heterogeneity within SLAM HSCs 
(Copley, Beer, & Eaves, 2012; Haas, Trumpp, & Milsom, 2018; Schroeder, 2010). More diligent 
studies on whether and how specified HSC subpopulations are distinctively regulated by 
different BM niches under homeostasis and stress conditions are required to improve our 
understanding of HSC maintenance in vivo, which may contribute to the discovery of safe 
technologies to promote functional HSC expansion in vitro without inducing cancerous 
transformations and lineage deficiencies.  
1.1.3    Master hematopoietic transcription factors 
Transcription factors dictate specific gene expression pattern in a cell to maintain cell 
identity and perform its unique function. A group of transcription factors has been found to play 
a pivotal role in the development and maintenance of HSCs. The transcription factors involved in 
programming endothelial-to-hematopoietic transition have drawn special interests as they may 
provide clues to de novo generation of HSCs from renewable cell types. TAL1/SCL and its 
associated partner, LMO2, are individually crucial for the development of both primitive and 
definitive hematopoietic systems (Hoang, Lambert, & Martin, 2016; Stanulovic, Cauchy, Assi, & 
Hoogenkamp, 2017). Blood cells cannot form in their absence. Similarly, deletion of Runx1 from 
VE-cadherin expressing cells abolishes HSC formation at the EHT stage, while knockout of 
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Runx1 in Vav1-expressing cells (potential HSCs) shows no hematopoietic deficiency, indicating 
that RUNX1 is required for the formation of “definitive” hematopoietic progenitors and HSCs 
but is dispensable once HSCs are specified (Cai et al., 2011; M. J. Chen, Yokomizo, Zeigler, 
Dzierzak, & Speck, 2009). In contrast, the expression level of GATA2 plays a crucial role during 
HSC development and function in adult BM, since haploinsufficiency or overexpression of 
GATA2 leads to HSC depletion or non-function (de Pater et al., 2013; Guiu et al., 2013; Lim et 
al., 2012; Ling et al., 2004).  
1.2       HSC expansion 
Except for the homeostasis condition, HSCs are also responsible for blood reconstitution 
in response to stress, rendering HSC transplantation a life-saving procedure in the treatment of a 
broad spectrum of disorders, including hematologic, immune, and genetic diseases (Walasek, 
van Os, & de Haan, 2012). Although the first successful HSC transplantation using human bone 
marrow from a related donor was accomplished 50 years ago in a boy with X-linked severe 
combined immunodeficiency disease (SCID) (Meuwissen, Gatti, Terasaki, Hong, & Good, 
1969), associated problems still need to be solved in the future to improve clinical outcomes. 
One of the problems is that many patients, especially those who possess genetic or epigenetic 
defects in their blood cells such as leukemia and myeloid disorders, require the transplantation of 
HSCs derived from genetically nonidentical donors, known as allogeneic transplantation. Despite 
the current widespread use of this approach (forty percent of one million hematopoietic cell-
transplantations performed) (Gratwohl et al., 2015), early studies suggested that allogeneic 
transplantation was only feasible when donors completely matched the recipient at the human 
leukocyte antigen (HLA) loci on both copies of chromosome 6 (Armitage, 1994; Thomas et al., 
1975). Two main classes of HLA proteins are known to exist: class I (A, B and C) and class II 
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(DP, DQ and DR). HLA class I molecules are constitutively expressed at variable levels by most 
cell types, while HLA class II genes are mainly expressed on the surface of hematopoietic cells, 
especially antigen-presenting cells (APCs), such as B cells, dendritic cells, macrophages and 
monocytes (Dendrou, Petersen, Rossjohn, & Fugger, 2018; Erlich, Opelz, & Hansen, 2001). 
However, even when HLA identically matched donors are used, graft-versus-host disease 
(GVHD), which occurs when immunocompetent T cells in the donated tissue (the graft) 
recognize the recipient (the host) as foreign, is still a common life-threatening complication, 
contributing to considerable mortality rate in patients received allogeneic HSC transplantation 
(Kanakry, Fuchs, & Luznik, 2016; Shlomchik, 2007). Furthermore, though HLA matching is 
critical to successful allogeneic HSC transplantation, only 20%-30% of patients have HLA-
matched sibling donors, meaning the majority of patients requiring HSC transplantation risk a 
deficit in HSC donors since the number of matched unrelated donors is limited by the extensive 
polymorphism of HLA genes. Thus, other sources of donor cells have been an urgent demand. If 
suitable donors are not found, umbilical cord blood (UCB), which can be procured both easily 
and safely, can be used. UCB has been shown to be a rich source of HSCs. Furthermore, the 
transplantation of UCB requires less-stringent HLA matching than does the transplantation of 
adult peripheral blood or marrow, because mismatched cord-blood cells are less likely to cause 
GVHD, without losing the graft-versus-leukemia effect (Wagner et al., 2002). However, the stem 
cell number in a single UCB unit is not sufficient for transplantation into an adult patient 
(Walasek et al., 2012). Significant effort has gone into developing technologies for ex vivo 




1.2.1    Extrinsic regulators of HSC self-renewal 
The fundamental base of HSC expansion relies on the ability to induce proliferation 
without compromising stemness, usually known as stem cell self-renewal. The aforementioned 
HSC niches and microenvironment play a crucial role in regulating HSC fate by secreting 
cytokines and producing physical and chemical factors to balance self-renewal and 
differentiation. Early studies about HSC culture have identified various cytokines for their ability 
to expand and maintain HSCs in vitro (Miller, Audet, & Eaves, 2002). For example, a 20-fold 
increase in phenotypic HSC expansion was reported in mice when cultured in vitro in 
combination with four cytokines, including SCF, TPO, IGF-2 and FGF-1 (C. C. Zhang & 
Lodish, 2005). However, clinical trials showed disappointing results with cytokine-expanded 
cord blood cells (Jaroscak et al., 2003). This may be explained by knowledge gained from 
cytokine studies indicating the insufficiency of these cytokines, by themselves, to support HSC 
self-renewal. In fact, they typically induce HSC differentiation, resulting at best in maintenance 
or modest stem cell amplification, but usually leading to progressive depletion of long-term 
repopulating cells (Walasek et al., 2012).  
Recently, factors that do not necessarily qualify as typical HSC growth factors but rather 
are involved in hematopoietic development have been shown to also regulate the expansion of 
HSCs ex vivo. These factors either stimulate or antagonize several developmentally conserved 
pathways, such as wingless-type (Wnt), Notch, sonic hedgehog (Shh), bone morphogenetic 
protein (BMP)/transforming growth factor β (TGF-β) and fibroblast growth factor (FGF).  
Multiple members of the family of secreted Wnt growth factors, as well as their cognate 
receptors, Frizzled (Fzd), and downstream effectors, including β-catenin and the LEF-1 family of 
transcription factors, have been documented to play a critical role in HSC maintenance both in 
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vivo and ex vivo (Luis, Ichii, Brugman, Kincade, & Staal, 2012). Interestingly, the effects of Wnt 
signaling are dosage and context dependent: low Wnt doses result in expansion of HSCs, 
whereas high doses cause exhaustion (Luis et al., 2011). Additionally, the effect of Wnt signaling 
exhibits discrepancy during different development stages: loss of β-catenin fails to affect 
homeostatic hematopoiesis and repopulation capacity of HSCs in adult mice, while loss of β-
catenin at embryonic stage impairs the expansion of the HSC pool, thereby compromising the 
long-term repopulation capacity and maintenance of hematopoiesis in adult mice (Cobas et al., 
2004; Jeannet et al., 2008; Koch et al., 2008; C. Zhao et al., 2007). Constitutive activation of β-
catenin alone results in apoptosis of HSCs. However, cooperative activation of both Wnt/β-
catenin and PTEN/PI3k/Akt pathways drives phenotypic LT-HSC expansion by inducing 
proliferation, while simultaneously inhibiting apoptosis and blocking differentiation (Perry et al., 
2011). In addition to canonical Wnt signaling, non-canonical Wnt signaling mediated by Fzd8, 
has been documented to maintain quiescent LT-HSCs by suppressing the Ca2+-NFAT- IFNγ 
pathway and antagonizing canonical Wnt signaling in HSCs. Loss of Fzd8 results in activation of 
quiescent LT-HSCs and deficiency in repopulation capacity after transplantation (Sugimura et 
al., 2012).  
Both Notch receptors and Notch ligands are expressed on HSCs and their niches, 
suggesting an interactive regulation of hematopoiesis between stem cells and microenvironment 
(Butko, Pouget, & Traver, 2016; Mendelson & Frenette, 2014). Studies on the role of the Notch 
pathway in HSC fate regulation show that an immobilized form of Notch ligand, Delta-1, but not 
its soluble form, can expand mouse and human HSPCs ex vivo. The expanded HSPCs exhibit 
long-term repopulation ability in immunodeficient recipient mice as shown after secondary 
transplantation. Intriguingly, the effect of Notch signaling, similar to that of Wnt signaling, was 
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suggested to be dose-dependent, since HSPC expansion was observed only with lower Delta-1 
concentrations (Delaney, Varnum-Finney, Aoyama, Brashem-Stein, & Bernstein, 2005; Varnum-
Finney, Brashem-Stein, & Bernstein, 2003; Varnum-Finney et al., 2000). However, clinical trials 
of transplantation of HSCs expanded via Notch signaling activation indicate that Delta-1 
treatment may result in expansion of committed myeloid progenitors occurs without maintenance 
of the pool of undifferentiated HSCs required for long-term engraftment (Nikiforow & Ritz, 
2016). 
Shh signaling-mediated human HSPC expansion appears to depend on downstream 
BMP-4 signaling, as inhibition of BMP-4 abolishes Shh-induced HSC expansion (Bhardwaj et 
al., 2001). BMP signaling has been shown to play a pivotal role in maintaining mouse HSC 
quiescence via control of the endosteal niche (J. Zhang et al., 2003). BMPs belongs to the TGF-β 
superfamily. TGF-β1, another secreted factor, is produced and activated by megakaryocytes and 
nonmyelinating Schwann cells, respectively, and is involved in maintaining HSC quiescence in 
the BM (Yamazaki et al., 2011; M. Zhao et al., 2014).  
The growing evidence has demonstrated that FGF signaling weighs into HSC regulation 
both in vivo and ex vivo. Addition of FGF-1 and FGF-2 in a serum-free medium of 
unfractionated mouse bone marrow cells supports the expansion of serial-transplantable HSCs 
(de Haan et al., 2003; Itkin et al., 2012). Loss of FGF receptor 1 (FGFR1,) which is expressed on 
HSCs, does not affect hematopoiesis homeostasis, but rather results in defects in HSC activation 
and proliferation in response to 5-fluorouracil (5FU) treatment (M. Zhao et al., 2012). This can 
be partially, if not entirely, due to loss of FGF signaling activation by FGF-1 secreted from 
megakaryocytes, which are a major resource for FGF after stress (M. Zhao et al., 2014).  
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1.2.2    HSC expansion by small molecules 
In recent years, much effort has been placed on screening chemical compounds, in 
addition to cytokines/factors, to expand HSCs ex vivo. Retinoid acid (RA), a metabolite of 
vitamin A (retinol), represents a natural small molecule that has been shown to be involved in 
hematopoiesis development and regulation of HSC dormancy, as well as treatment for acute 
promyelocytic leukemia by induction of leukemic cell differentiation (Cabezas-Wallscheid et al., 
2017; Degos & Wang, 2001). However, the role of RA in ex vivo HSPC expansion is unclear. 
Furthermore, the effect of RA on balancing HSC self-renewal and differentiation depends on 
exquisite regulation of RA dosage in the microenvironment (Ghiaur et al., 2013). More 
investigations are required before applying RA into clinical HSC expansion.  
Recent studies have reported the ability to identify novel small molecules with HSC self-
renewal stimulatory activity, thus potentially applying to HSC expansion. Taking advantage of 
high-throughput screening, Boitano et al. identified a purine derivative, referred to as 
StemRegenin 1 (SR1), which was capable of enhancing human CD34+ HSC cell expansion ex 
vivo via antagonizing aryl hydrocarbon receptor (AhR) pathway (Boitano et al., 2010). Though 
SR1 increases UBC CD34+ cell expansion by 17-fold, it does not support ex vivo expansion of 
mouse HSCs or adult human HSCs. Recently, Kristin Hope’s lab reported that overexpression of 
Musashi-2 is able to expand long-term repopulating human HSCs by attenuating AhR signaling 
(Rentas et al., 2016). AhR is a member of the Pern-Arnt-Sim (PAS) superfamily of transcription 
factors that are involved in sensing environmental signals such as toxins (Gutierrez-Vazquez & 
Quintana, 2018). AhR has been well documented to regulate adaptive immunity, modulating T 
cell differentiation, especially playing an important role in Treg cell development. Thus, it is 
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notable to evaluate the efficiency and capacity of immune reconstitution from HSCs expanded 
with SR1 after transplantation into patients.  
Another novel compound, a pyrimidoindole derivative named as UM171 that was 
identified in a chemical library screen, was shown to expand human CD34+CD45RA–mobilized 
peripheral blood cells (Fares et al., 2014). Unlike SR1, UM171 does not target AhR pathway. 
However, the physiological targets of UM171 remain unclear. In the Fed-Batch culture system, 
UM171 facilitates expansion of hematopoietic progenitors and results in a 13-fold expansion of 
functional LT-HSCs. However, HSCs expanded with UM171 exhibit a lymphoid-deficient 
differentiation pattern in transplantation recipient mice.  
1.2.3    Intrinsic regulators of HSC self-renewal 
Accumulating knowledge has demonstrated the important role of intrinsic factors in 
regulating HSC self-renewal. One of the first studies of HSC expansion via manipulating of 
intrinsic factor shows that ectopic expression of transcription factor, Hoxb4, results in 40-fold 
expansion of repopulating mouse HSCs without inducing leukemia (Amsellem et al., 2003; 
Antonchuk, Sauvageau, & Humphries, 2002). However, while human CD34+ HSPCs expressing 
Hoxb4 expand significantly in immunodeficient recipient mice, differentiation of these cells into 
lymphoid and myeloerythroid lineages is impaired when levels of Hoxb4 are high (Schiedlmeier 
et al., 2003), suggesting the exquisite balance of stem cell self-renewal and differentiation needs 
to be taken care before clinical application. Additionally, a retinoid-dependent cis-regulatory 
element that coordinates regulation of Hoxb expression, has been shown to play a pivotal role in 
HSC maintenance (Qian et al., 2018). Augmentation of HSC self-renewal can also be achieved 
by overexpression of chromatin remodelers, such as members of the Polycomb group (PcG) 
family of proteins, especially zeste (Ez) proteins (Ezh1, Ezh2) and B cell-specific Moloney 
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murine leukemia virus integration site 1 (Bmi1) (Hidalgo et al., 2012; Iwama et al., 2004; 
Kamminga et al., 2006; Rizo, Dontje, Vellenga, de Haan, & Schuringa, 2008). Interestingly, loss 
of Dnmt3a, a de novo DNA methyltransferase, immortalizes HSC in vivo at the expense of 
differentiation capacity, rendering very high risk of developing leukemia once mutation occurs 
(Challen et al., 2011; Jeong et al., 2018; Shlush et al., 2014). In line with this, alterations of 
epigenetic modifications or mutations of epigenetic regulators have been strongly linked to 
tumorigenesis and leukemogenesis (Makova & Hardison, 2015; Ntziachristos, Abdel-Wahab, & 
Aifantis, 2016).   
1.3      RNA m6A modification 
RNA modifications have been well documented for over 50 years with the first discovery 
of pseudouridine in abundant RNAs extracted from yeast (Cohn, 1960). Subsequent studies have 
further identified over 100 types of RNA nucleotide modifications on various RNA types, 
including messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), transfer-
messenger RNA (tmRNA), small nuclear RNA (snRNA), and chromosomal RNA (Cantara et al., 
2011). These modifications not only mark and regulate these transcripts, but also diversify and 
extend information from the simple genetic code in DNA. Here, we focus on the more recent 
discoveries in mRNA modifications, especially N6-methyladenosine (m6A) methylation, that 
have shown a profound effect on biological systems. 
1.3.1    m6A writers, erasers and readers 
m6A is the most abundant internal modifications in eukaryotic mRNA and was first 
discovered in the 1970s (Adams & Cory, 1975; Desrosiers, Friderici, & Rottman, 1974; Furuichi 
et al., 1975; Lavi & Shatkin, 1975; Wei & Moss, 1975). Mammalian mRNA m6A methylation 
sites were first found in 1984, and measurements from mass spectrophotometry suggested the 
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amount of m6A in total RNA was estimated to be 0.1%-0.4% of all adenosine nucleotides in 
mammals (Horowitz, Horowitz, Nilsen, Munns, & Rottman, 1984). However, due to the low 
amount of m6A in mRNA and lack of technologies with high sensitivity, studies to characterize 
the function of m6A did not significantly progress until 2012. At that time, techniques using a 
m6A specific antibody for methylated RNA immunoprecipitation, followed by high-throughput 
sequencing, were developed and facilitated the generation of transcriptome-wide maps of m6A, 
charting the m6A epitranscriptome (Dominissini et al., 2012; Meyer et al., 2012).  
RNA m6A modification is catalyzed by a multicomponent methyltransferase complex 
that was first reported in 1994 (Bokar, Rath-Shambaugh, Ludwiczak, Narayan, & Rottman, 
1994). The complex is composed of catalytic enzyme, methyltransferase-like 3 (METTL3), and 
cofactors, including METTL14, Wilms tumor 1‑associated protein (WTAP) and KIAA1429 
(Bokar, Shambaugh, Polayes, Matera, & Rottman, 1997; J. Liu et al., 2014; Ping et al., 2014; 
Schwartz, Mumbach, et al., 2014; Y. Wang et al., 2014). The METTL3 complex recognizes and 
methylates mRNAs at conserved RRACH motifs (R = A or G; H = A, C, or U) across various 
species, often in mRNA 3′ UTRs and coding DNA sequence (CDS) (Dominissini et al., 2012; Ke 
et al., 2015; Meyer et al., 2012; Yue, Liu, & He, 2015). Recently, another m6A 
methyltransferase, METTL16, has been identified and shown to deposit m6A in U6 snRNA and 
pre-mRNAs, regulating the alternative splicing through intron retention (Gu, Patton, Shimba, & 
Reddy, 1996; Pendleton et al., 2017b; Sergiev, Serebryakova, Bogdanov, & Dontsova, 2008; 
Warda et al., 2017). Notably, METTL16 methylates the conserved sequence, UACAGAGAA, in 
U6 snRNA and methionine adenosyltransferase 2A (MAT2A) pre-mRNA, thereby regulating the 
expression of MAT2A in response to intracellular S-adenosylmethionine (SAM) level (Pendleton 
et al., 2017b). 
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RNA m6A modification is dynamic and reversible, attributed to the discovery of two 
demethylases catalyzing the oxidative demethylation of m6A: one is fat-mass and obesity-
associated protein (FTO), the first demethylase identified to reverse m6A modifications in 
nuclear RNA (Jia et al., 2011); a second m6A demethylase of the same family, α-ketoglutarate-
dependent dioxygenase alkB homolog 5 (ALKBH5), affects mouse fertility and spermatogenesis 
(Zheng et al., 2013). The identification of both these enzymes and characterization of their 
function on demethylation of m6A in mRNA provided the first evidence of reversible post-
transcriptional modification in RNA transcribed by RNA polymerase II, including mRNAs and a 
set of non-coding RNAs.  
The biological function of RNA m6A modification is exerted by the m6A-binding 
proteins or called “readers”. Rechavi and colleagues initially identified YTH-domain-containing 
proteins, YTHDF2 and YTHDF3 as m6A reader proteins in an m6A RNA pull down experiment 
without characterizing their function (Dominissini et al., 2012). There are five members of YTH-
domain proteins in mammalian cells: YTHDF1–3, which are primarily localized in the 
cytoplasm, and YTHDC1 and YTHDC2, which exhibit nucleus localization (Patil et al., 2016; X. 
Wang et al., 2014; X. Wang et al., 2015; Xu et al., 2014). The study of YTHDF2 in Hela cells 
showing the regulatory function of YTHDF2 on expediting m6A-modified mRNA decay 
provides the first evidence of m6A reader protein involving in significant biological functions (X. 
Wang et al., 2014). In contrast to YTHDF2, YTHDF1 does not show a considerable effect on 
mRNA decay, instead it is shown to promote translation by interacting with eIF3 and other 
translation initiation factors (X. Wang et al., 2015). The function of YTHDF1 on translation 
regulation can be enhanced by cooperating with another YTH-domain protein, YTHDF3, which 
interacts with ribosomal 40S/60S subunits (A. Li et al., 2017; Shi et al., 2017b). YTHDC1, a 
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nucleus-enriched splicing regulator before it was known to interact with m6A, has been 
demonstrated its role in m6A-regulated splicing and mRNA export from nucleus (Roundtree et 
al., 2017; Xiao et al., 2016). YTHDC1 is also shown to mediate the function of XIST, a 
noncoding RNA that contains at least 76 m6A sites and is critical for silencing genes on one X 
chromosome in female cells (Lee, 2009; Patil et al., 2016). The function of another m6A reader 
protein, YTHDC2, remains poorly understood. Recent studies show that YTHDC2 regulates the 
transition from proliferation to differentiation in the germline by enhancing the translation 
efficiency of its targets and also decreasing their mRNA abundance (Bailey et al., 2017; P. J. Hsu 
et al., 2017). In addition to YTH-domain containing proteins, other m6A reader proteins, include 
HNRNPA2B1 and insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) (Alarcon, 
Goodarzi, et al., 2015; Huang et al., 2018). 
1.3.2    mRNA m6A modification in disease and development 
Recent studies have elucidated the roles of m6A modification in stem cell fate 
determination and endothelial-to-hematopoietic transition during embryogenesis (Batista et al., 
2014; Geula et al., 2015; Lv et al., 2018; Yoon et al., 2017b; C. Zhang et al., 2017b; B. S. Zhao, 
Wang, et al., 2017b) as well as in leukemia development (Barbieri et al., 2017b; Z. Li et al., 
2017b; Vu et al., 2017b; Weng et al., 2018). Interestingly, deficiency in m6A writer complex, 
METTL3 and METTL14, leads to distinct outcomes in different types of stem cells. For 
example, Mettl3 or Mettl14 KO promoted differentiation in HSCs (Barbieri et al., 2017b; Vu et 
al., 2017b; Weng et al., 2018), while resulting in enhanced stem cell self-renewal and 
maintenance in mouse embryonic stem cells (mESCs) and embryonic neuronal stem cells 
(NSCs) (Batista et al., 2014; Yoon et al., 2017b). Besides, the physiological function of m6A in 
stem cells and leukemia are mediated through different mechanisms. In stem cells, m6A 
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modifications regulate stem cell fate determination by m6A-mediated decay of mRNAs encoding 
stem cell fate determinant (Batista et al., 2014; Yoon et al., 2017b), while in acute myeloid 
leukemia (AML), METTL3 and METTL14 promote leukemogenesis as m6A modifications 
stabilize the mRNAs of oncogenes and/or increase their translation (Barbieri et al., 2017b; Vu et 
al., 2017b; Weng et al., 2018). Furthermore, previous studies have reported that the 
leukemogenic functions of FTO and METTL14 are independent of YTHDF reader proteins (Z. 
Li et al., 2017b; Weng et al., 2018). Noting that, we focus on Ythdf2, a well-recognized m6A 
reader promoting targeted mRNA decay to investigate its role in the context of HSC 
maintenance. We hypothesize that manipulation of Ythdf2 might potentially influence the life 
span of a great number of m6A-marked mRNAs, thus impacting adult HSC self-renewal versus 





Chapter 2 : Materials and Methods 
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2.1      Mice. 
Ythdf2 conditional KO mice were generated by Chuan He and Bin Shen group. Mice 
were housed in the animal facility at Stowers Institute for Medical Research (SIMR) and handled 
according to Institute and NIH guidelines. All procedures were approved by the IACUC of 
SIMR. 
2.2       Flow cytometry and HSPC sorting.  
Mouse HSPCs, progenitors, and lineage cells were harvested from BM (femur and tibia) 
and spleen. Red blood cells were lysed using a 0.16 M ammonium chloride solution, and the 
cells were filtered with 70μm strainers to generate single cell suspensions. For mouse HSC 
identification, cells were stained with antibodies against Sca-1 (D7), c-Kit (2B8), CD34 
(RAM34), Flk2 (A2F10), CD48 (HM48-1), CD150 (TC15-12F12.2), together with lineage 
cocktail including CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), Mac-1 (M1/70), Gr1 (RB6-
8C5), CD45R (B220, RA3-6B2), IgM (Il-41) and Ter119 (TER-119). For progenitors and 
lineage cells, cells were stained with antibodies as previously described (Qian et al., 2016). 7-
aminoactinomycin D (7-AAD) (A1310, Life technologies) was used to exclude dead cells. hUCB 
samples were acquired from the St. Louis Cord Blood Bank. Mononuclear cells were isolated 
with Lymphoprep™ (StemCell technologies), followed by isolation of human CD34+ cord blood 
cells by human CD34 MicroBead Kit UltraPure (Miltenyi Biotec). To quantify hUCB HSPCs, 
cells were stained with antibodies against CD34 (581), CD38 (HIT2), CD45RA (HI100), CD90 
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(5E10), CD49f (GoH3), EPCR/CD201 (RCR-401). Cell sorting and analyses were performed on 
MoFlo (Dako), InFlux Cell Sorter (BD Biosciences), and/or MACSQuant (Miltenyi Biotec). 
Data analysis was performed using FlowJo software. 
2.3       Homing assay.  
In vivo homing assays were performed as previously described (X. C. He et al., 2014). 
Basically, whole bone marrow (WBM) cells from CD45.2 mice were labelled with 5 μM 5-(and -
6)-carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (Molecular Probes) at 37˚C for 
10 mins, washed three times, and 1×106 WBM were transplanted into lethally irradiated ptprc 
mice. After 18 hours, femurs and tibias were flushed, and CFDA SE+ cells were determined.  
2.4       Competitive reconstitution assay.  
Competitive reconstitution assays were performed by intravenous transplantation of 2 
×105, 7.5 ×104 or 2.5 ×104 donor-derived WBM cells from wt or Ythdf2 KO mice (CD45.2), 
together with 2×105 rescue cells (CD45.1) into groups of ten lethally irradiated (10 Gy) ptprc 
recipient mice. For secondary transplantation, primary transplant recipients were sacrificed. BM 
cells were dissected from femur and tibia, and then transplanted mouse-to-mouse at a dosage of 
1×106 cells into irradiated secondary recipient mice. Baytril water was given to recipient mice 
three days before irradiation and continued for another two weeks after irradiation. Primary and 
secondary competitive repopulating unit (CRU) frequencies were measured using ELDA 
software (Hu & Smyth, 2009), in which successful engraftment was defined as the presence of a 
distinct CD45.2+ CD45.1- population ≥5% and ≥1% of total hematopoietic cells in peripheral 
blood, respectively (Purton & Scadden, 2007). Also, the secondary transplantation recipient mice 
that died before 16 weeks post transplantation were counted for failed engraftment.   
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For rescue experiment, LSK cells were sorted out from wt and Ythdf2 KO mouse BM and 
cultured overnight in StemSpan SFEM medium (Stem Cell Technologies) supplemented with 
10μg/mL heparin (Sigma), 0.5× penicillin/streptomycin (Sigma), 10ng/mL recombinant mouse 
(rm) SCF (Biovision, Inc.), and 20ng/mL Tpo (Cell Sciences, Inc.) (Perry et al., 2011) at 37⁰C 
5% CO2 5% O2. Control shRNA and shRNA targeting mouse Tal1 were delivered into LSK cells 
by lentivirus at 100 MOI. To enhance the efficiency of infection, ViroMag Transduction 
Reagent (OZ Biosciences) were used following manufacturer’s directions. GFP+ cells were 
sorted out at 5 days post infection and cultured for another 3 days to expand before 
transplantation. Upon transplantation, equal numbers of GFP+ cells from each group were 
transplanted with 105 rescue BM cells into lethally irradiated recipients.  
2.5      Cell cycle and apoptosis assays.  
Cell cycle analysis was performed with FITC mouse anti-human Ki67 set (BD 
Pharmingen) according to the manufacturer’s instructions. Briefly, 5×106 BM cells were isolated 
and stained with HSC antibodies as described above. Cells were fixed by 4% paraformaldehyde 
at 4˚C overnight or room temperature (RT) for 1 hour, and then permeabilized with 0.2% triton 
X-100 on ice for 15 mins. Cells were washed with PBS containing 2% FBS, and then were 
incubated with Ki-67 antibody at RT for 1 hour in the dark, and SYTOX Red (Invitrogen) at RT 
for another 5 mins, followed by flow cytometric analysis with InFlux Cell Sorter (BD 
Biosciences). For apoptosis analysis, Annexin V (Invitrogen) and SYTOX Red staining of 5×106 
BM cells was performed according to the manufacturer’s protocol.  
2.6       m6A RNA-IP-seq. 
Two replicates of 105 LT-HSC (LSK CD34- Flk2-), ST-HSC (LSK CD34+ FLK2-) and 
MPP (LSK CD34+ FLK2+) from C57BL/6J mouse were sorted into TRIzol (Invitrogen), and total 
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RNA was isolated according to the manufacturer’s instructions. RNA was fragmented to ~100 
nucleotide fragments with Ambion fragmentation reagent (2 mins incubation at 70⁰C). The 
samples were then subjected to Turbo DNase treatment (Ambion), followed by a phenol-
chloroform extraction, and resuspension in 85μl of nuclease-free water, and 5μl was saved as 
input. Then the remaining 80μl RNA fragments were diluted into IPP buffer (150mM NaCl, 
0.1% NP-40, 10mM Tris-HCl, pH 7.5). RNA was incubated with 25μl of protein-G magnetic 
beads, previously bound to 3μg of anti-m6A plyclonal antibody (Synaptic Systems), for 3 hours 
at 4⁰C in IPP buffer. Beads were washed twice with 200μl IPP buffer, twice with 200μl low-salt 
buffer (50mM NaCl, 0.1% NP-40, 10mM Tris-HCl, pH 7.5) and twice with 200μl high-salt 
buffer (500mM NaCl, 0.1% NP-40, 10mM Tris-HCl, pH 7.5). Beads were then treated with 
300μl Elution Buffer (5mM Tris-HCL pH 7.5, 1mM EDTA pH 8.0, 0.05% SDS, 4.2μl Proteinase 
K (20 mg/ml)) for 1.5 hours at 50⁰C, and RNA was recovered with phenol:chloroform extraction 
followed by ethanol precipitation. Three human CD34+ umbilical cord blood cells were isolated 
as described above and isolated total RNA with TRIzol. RNA was fragmented to ~100 
nucleotide fragments with Ambion fragmentation reagent (2 mins 50 secs incubation at 70⁰C). 
The samples were then subjected to Turbo DNase treatment (Ambion), followed by a 
phenol:chloroform extraction, and resuspension in 18μl of nuclease-free water, and 1μl was 
saved as input. m6A RNA IP was performed with EpiMark® N6-Methyladenosine Enrichment 
Kit following manufacturer’s instructions.  
Following m6A preparation of RNA, quality was assessed on Agilent 2100 Bioanalyzer, 
and 1ng (mouse) or 10ng (human) RNA was used to generate RNAseq libraries according to the 
manufacturer’s directions for the SMARTer Stranded Total RNA-Seq Kit – Pico Input 
Mammalian (Takara Bio Inc) using 16 cycles (mouse) or 13 cycles (human) PCR2 amplification.  
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This method uses random priming and a template switching oligo to generate complimentary 
DNA, followed by the ligation of barcoded adapters; ribosomal-derived cDNA is then removed 
through probe-directed enzyme cleavage and subsequent enrichment of un-cleaved fragments.  
We modified the protocol to retain lower molecular weight sample fragments by using a 1.2x 
SPRI bead concentration for PCR1 cleanup. To remove dimerized adapters, libraries underwent 
160-600 bp size selection with a Pippin Prep (Sage Science) 2% gel. The resulting libraries were 
checked for quality and quantity using the Bioanalyzer and Qubit Fluorometer (Life 
Technologies). Then equal molar libraries were pooled and requantified. For mouse m6A-seq, 
libraries were sequenced as 50 bp single read on the Illumina HiSeq 2500 instrument using 
HiSeq Control Software 2.2.58. Following sequencing, Illumina Primary Analysis version RTA 
1.18.64 and Secondary Analysis version bcl2fastq2 v2.18 were run to demultiplex reads for all 
libraries and generate FASTQ files. For human m6A-seq, libraries were sequenced as 75 bp 
single read on the Illumina NextSeq instrument using NextSeq Control Software 2.1.2. 
Following sequencing, Illumina Primary Analysis version NextSeq RTA 2.4.11 and Secondary 
Analysis version bcl2fastq2 v2.18 were run to demultiplex reads for all libraries and generate 
FASTQ files. 
2.7       Plasmid construction and stable cell line generation.  
Mouse Ythdf2 (mYthdf2) was cloned from commercial cDNA clone (ORIGENE # 
MC200730) into vector pcDNA5/FRT/Flag plasmid using primers listed: mYthdf2 ORF Clone 
BamhI F: 5’-CGC GGA TCC TCG GCC AGC CTC TTG GA-3’ and mYthdf2 ORF Clone NotI 
R: 5’-ATA AGA ATG CGG CCG CCT ATT TCC CAC GAC CTT GAC GT-3’. Then Flag-
mYthdf2 was subcloned under EF1a promoter in pSicoR-EF1a-IRES-EGFP lentiviral construct 
(Gibson Assembly®, forward primer: 5’-GTC GAC GGT ACC GCG GGC CCA TGG ATT 
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ACA AGG ATG ACG ACG-3’ and reverse primer: 5’-GAG GGA GAG GGG CGG ATC CCC 
TAT TTC CCA CGA CCT TGA CGT-3’). Human Ythdf2 (hYthdf2) was cloned from plasmid 
provided by Chuan He lab using primers indicated: Forward 5’-CGT TCG AAA TGT CGG 
CCA GCA GCC TCT-3’; Reverse 5’-TCC CCC GGG TTA TTT CCC ACG ACC TT-3’. Then 
hYthdf2 was cloned into pSicoR-EF1a-IRES-EGFP constructs under EF1a promoter by BstBI 
and XmaI restriction digestions and ligation. To generate Flag-mYthdf2 HPC7 stable cell line, 
lentiviruses were generated by transfection of pSicoR-EF1a-Flag-mYthdf2-IRES-EGFP 
constructs together with the psPAX2 and pMD2.G plasmids at a ratio of 10:7.5:2.5 into 293T 
cells using calcium phosphate transfection. The virus particles were harvested 48, 72, and 96 
hours post transfection, filtered by 0.45 micrometers filter unit (Millipore), and then centrifuged 
at 18,000 RPM, 4˚C for 2 hours. HPC7 cells were infected with recombinant lentivirus-
transducing units in the presence of 4μg/mL polybrene (Sigma). 48 hours after infection, GFP+ 
cells were sorted and cultured for experiments.  
2.8       irCLIP-seq and data analysis. 
For irCLIP-seq, we modified the procedure from the previously reported methods 
(Simsek et al., 2017; Zarnegar et al., 2016). In brief, irCLIP was performed on ~3×108 Flag-
Ythdf2 HPC7 cells by UV crosslinking cells at 0.4J/cm2 for 3 times. Whole-cell lysates were 
generated in lysis buffer (150mM KCl, 10mM HEPES pH 7.6, 2mM EDTA, 0.5% NP-40, 
0.5mM DTT, 1:100 protease inhibitor cocktail, 400U/ml RNase inhibitor; 1ml cell pellet and 2ml 
lysis buffer). Pipetted up and down several times, and then the mRNP lysate was incubated on 
ice for 5 mins and shock-frozen at -80⁰C with liquid nitrogen. The mRNP lysate was thawed on 
ice and centrifuged at 15,000g for 15 mins to clear the lysate. Flag-Ythdf2 was isolated with 30μl 
of protein-G magnetic beads per 1ml lysate, previously bound to 2μg of anti-Flag monoclonal 
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antibody (Sigma) for 2 hours at 4⁰C on rotation. The beads were collected, washed eight times 
with 1ml ice-cold NT2 buffer (200mM NaCl, 50mM HEPES pH 7.6, 2mM EDTA, 0.05% NP-
40, 0.5mM DTT, 200U/ml RNase inhibitor) and one time with 200μl irCLIP NT2 buffer (50mM 
Tris, pH 7.5; 150mM NaCl; 1mM MgCl2; 0.0005% NP-40). mRNP complex was digested with 
RNase 1 (Thermo Fisher #AM2294) at 0.4U/μl in irCLIP NT2 buffer (aqueous volume of 30μl 
and supplemented with 6 μl of PEG400 (16.7% final)). The nuclease reaction was incubated at 
30⁰C for 15 mins in an Eppendorf Thermomixer, 15 s 1,400 r.p.m., 90 s rest. Nuclease digestions 
were stopped by addition of 0.5mL of ice-cold high-stringency buffer (20mM Tris, pH 7.5; 
120mM NaCl; 25mM KCl; 5mM EDTA; 1% Trition-X100; 1% Na-deoxycholate). 
Immunoprecipitates were then quickly rinsed with 0.25mL then with 0.05mL of ice-cold irCLIP 
NT2 buffer. The irCLIP adaptor ligation and library construction followed previously reported 
protocol (Zarnegar et al., 2016).  
Data were demultiplexed using FAST-iCLIP version 0.9.3 and aligned to mouse genome 
mm10 from UCSC using STAR (2.4.2a) with parameters "--outFilterScoreMinOverLread 0 --
outFilterMatchNminOverLread 0 --outFilterMatchNmin 0". RPM-normalized genome browser 
tracks were created in R (3.4.1) and plotted using the Gviz package (1.20.0). Enriched motifs 
were identified by taking midpoints of each binding site found in all three replicates, adding 20 
bases up and downstream, and running MEME (4.11.1) with parameters "-dna -mod zoops -
revcomp -minw 5 -maxw 10 -nmotifs 10 -maxsize 1000000". After motifs were identified, we 
ran tomtom (4.11.1) against transfac (1-2017) to identify known binding sites. Gene Ontology 
enrichment analysis was performed using a hypergeometric test in R. GO terms were considered 
enriched if they had a BH-adjusted p-value less than 0.05. Selected terms of interest are shown in 
the bar plot. Bars in the bar plot indicate percentage of genes in the list being tested having the 
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term divided by the percentage of genes in the genome having the term. Peaks found by FAST-
iCLIP in all three replicates were assigned to various features in the genome. Promoters were 
defined as upstream 150 bases from the TSS. "trans_stop" was defined as upstream and 
downstream 200 bases from the transcript start site. 
2.9       Cord blood transduction. 
Cord blood transduction was conducted as described previously (Rentas et al., 2016). 
Briefly, fresh CD34+ cord blood cells or flow-sorted CD34+ CD38- cells were prestimulated for 
12-18 hours in StemSpan medium (StemCell Technologies) supplemented with growth factors 
interleukin 6(IL-6; 20ng/ml, Peprotech), stem cell factor (SCF; 100ng/ml, Peprotech), Flt3 ligand 
(FLT3-L; 100ng/ml, Peprotech) and thrombopoietin (TPO; 20ng/ml, Peprotech). Lentiviruses 
were then added in the same medium at a multiplicity of infection (MOI) of 50-200 for 24 hours. 
Cells were then given 2 days after transduction before in vitro or in vivo assays. Human YTHDF2 
was knockdown by shRNA targeting 5’-AAGGACGTTCCCAATAGCCAA-3’ near the N 
terminus of CDS as used in a previous report (Shlush et al., 2014). Scramble shRNA (seed 
sequence 5’- GCGCGATAGCGCTAATAAT-3’) was used as control. 
2.10    Clonogenic progenitor assays. 
Flow-sorted GFP+ cord blood cells from 10-day cultured transduced cells (12,000 per ml) 
were resuspended in semi-solid methylcellulose medium (Methocult H4034; StemCell 
Technologies). Colony counts were carried out after 14 days of incubation.  
2.11     Human umbilical cord blood HSPC culture. 
Two days after transduction, human cord blood CD34+ or CD34+ CD38- cells were 
collected and determined GFP+ percentage by flow cytometry. To ensure that equal numbers of 
GFP+ cells were cultured before expansion, we added identically cultured GFP- cells to the one 
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with higher GFP+ percentage to match the % GFP+ between control and hYthdf2 KD. Then cells 
were seeded at a density of 105 per ml in StemSpan medium (StemCell Technologies) 
supplemented with growth factors IL-6 (20ng/ml), SCF (100ng/ml), FLT3-L (100ng/ml), TPO 
(20ng/ml) and CHIR99021 (250 nM) (Stemgent)(Perry et al., 2011).  
2.12     Human HSC xenotransplantation. 
For human cord blood HSC ex vivo expansion analysis, 105 sorted CD34+ CD38- cells 
were transduced with human YTHDF2 shRNA or control shRNA for 3 days and then analyzed 
for transduction efficiency (%GFP-/+) and stem cell markers. On day 10, cultured cells were 
collected for stem cell marker analysis. For hUCB HSC primary limiting dilution assay (LDA), 
CD34+ cells were enriched as described above and transduced with human YTHDF2 shRNA or 
control shRNA at 50 MOI. Media were changed at 24 hours post infection. Equal number of 
GFP+ cells were sorted out from control or YTHDF2 KD cells on 3 days post infection and 
cultured overnight. Three doses, 50K, 20K and 10K, of sorted GFP+ cells were transplanted into 
sublethally irradiated (3.25Gy) NSG mice, respectively. The cut-off for HSC engraftment was an 
exhibition of more than 1% human CD45+ GFP+ cells out of total CD45+ cells in BM of primary 
transplantation recipients. For hUCB HSC secondary LDA assay, BM cells from highest two 
doses primary recipients were collected and mixed together at 10 weeks post transplantation. 
Three doses, 1.2 × 107, 8 × 106, 4 × 106, of BM cells were transplanted into sublethally irradiated 
(3.25Gy) NSG mice, respectively. The cut-off for HSC engraftment was an exhibition of more 
than 0.2% human CD45+ GFP+ cells out of total CD45+ cells in BM of secondary transplantation 
recipients. HSC frequency was assessed using ELDA software (Hu & Smyth, 2009). For all 




2.13     m6A-seq data analysis. 
Human and mouse m6A-seq data were aligned to the transcriptome of hg19 and mm10. In 
order to identify m6A peaks, hg19 and mm10, transcriptome was divided into 25 nucleotide-wide 
tiles. The number of reads in the m6A IP and non-IP (control) sample was counted in each tile, 
and p value was calculated with Fisher exact test and adjusted for multiple testing. Tiles with 
significant m6A signal enrichment (adjust-Pval <= 0.05) were merged into bigger regions. 
Regions smaller than 100 bp were discarded, and regions over 200 bp were divided into 100 to 
200 bp sub-regions; m6A signal over control was calculated at each region; and regions with at 
least 2-fold enrichment in all replicates were identified as m6A peaks. m6A peaks distribution 
and m6A marked genes were determined by overlapping all m6A peaks with hg19 and mm10 
RefGene annotation. m6A marked genes were identified by overlapping m6A peaks with hg19 
RefGene. To filter for transcription factors, genes marked by m6A in all three samples were 
compared against human transcription factor database 
(http://fantom.gsc.riken.jp/5/sstar/Browse_Transcription_Factors_hg19).  GO term analysis was 
then performed using R package enrich GO. m6A marked human transcription factors were used 
as searching list, and all the expressed genes were used as background. Hemopoiesis related BP 
terms with significant enrichment were used to generate Figure 3c. 
2.14     RNA-seq. 
Human cord blood CD34+ cells were transduced with control or human YTHDF2 KD 
lentivirus and sorted out for GFP+ CD34+ 10 days later. Three replicates of 12,000 GFP+ CD34+ 
cells were sorted for each group and were used to extract total RNA. Four nanograms of high 
quality total RNA was used for cDNA synthesis and library preparation according to the 
manufacturer’s directions with the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing 
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(Takara, 634891) and Nextera XT (Illumina, FC-131-1096). Resulting short fragment libraries 
were checked for quality and quantity using an Agilent 2100 Bioanalyzer and Invitrogen Qubit 
Fluorometer. Equal molar libraries were pooled, requantified, and sequenced as 75 base pair 
single reads on a High Output flow cell on the Illumina NextSeq 500 instrument. Following 
sequencing, Illumina Primary Analysis version NextSeq RTA 2.4.11 and Secondary Analysis 
version bcl2fastq2 2.18 were run to demultiplex reads for all libraries and generate FASTQ files.  
For RNA-seq analysis, reads were aligned to UCSC genome hg38 with Tophat version 
2.0.13 with default parameters, using Ensembl 87 gene models. Read counts were generated 
using HTSeq-count with -m intersection-nonempty. Reads were also aligned to ERCC control 
sequences and counts tabulated. A scaling factor was calculated based on the median of the 
ERCC counts for each sample and used for normalization. Differentially expressed genes were 
found using the edgeR package (3.18.1) in R (3.4.1). Differentially expressed genes were 
required to have a BH-adjusted p-value < .05 and a 2-fold change in expression. 
2.15     RNA stability assay. 
15,000 sorted LT-, ST-HSCs and MPPs were cultured in StemSpan SFEM medium (Stem 
Cell Technologies) supplemented with 10μg/mL heparin (Sigma), 0.5× penicillin/streptomycin 
(Sigma), 10ng/mL recombinant mouse (rm) SCF (Biovision, Inc.), and 20ng/mL Tpo (Cell 
Sciences, Inc.) (Perry et al., 2011) at 37⁰C 5% CO2 5% O2. Sorted cells were treated with 5μM 
actinomycin D (Sigma) for inhibition of mRNA transcription. Cells were harvested at 0 hour or 4 
hours post treatment, and total RNA was extracted and used for RNA-seq.  
2.16     m6A RNA methylation quantification. 
Mouse BM Lineage negative cells from wt and Ythdf2 KO mice were enriched with 
mouse Lineage Cell Depletion Kit (Miltenyi Biotec), followed by total RNA extraction with 
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TRIzol (Invitrogen). The quantification of m6A RNA methylation in Lin- cells were performed 
with m6A RNA Methylation Quantification Kit (Abcam ab185912) following manufacturer’s 
protocol. 200ng total RNA were used per replicates for either group.  
 
2.17     qPCR analysis. 
105 LSK cells were sorted from wt and Ythdf2 KO mice. Total RNA was extracted with 
TRIzol (Invitrogen). cDNA synthesis was conducted with High-Capacity RNA-to-cDNA™ Kit 
(Thermo) following manufacturer’s protocol. qPCR primers used are listed Table 2.1.  
mouse Tal1 qPCR primer F CGCTGCTCTATAGCCTTAGCC
mouse Tal1 qPCR primer R CTCTTCACCCGGTTGTTGTT
mouse Gata2 qPCR primer F CAACCCTTACTACGCCAACC
mouse Gata2 qPCR primer R GCTGTGCAACAAGTGTGGTC
mouse Runx1 qPCR primer F CCAGCCTCTCTGCAGAACTT
mouse Runx1 qPCR primer R GGAGATGGACGGCAGAGTAG
mouse Stat5a qPCR primer F AGAAGCAAGTGTCCCTGGAG
mouse Stat5a qPCR primer R GTCGTCCAGGATGATGGTCT
mouse Actb qPCR primer F TGTCACCAACTGGGACGATA
mouse Actb qPCR primer R ACCCTCATAGATGGGCACAG  
Table 2.1 qPCR primers used to verify the expressional levels of transcription factors in wt 
and Ythdf2 KO HSPCs. 
 
2.18     Western blot and intracellular staining. 
To validate the KO or KD efficiency in Ythdf2 KO mouse model or hUCB, 33,000 cKit+ 
cells or 120,000 GFP+ cells were sorted from BM or transfected hUCB samples, respectively. 
Hela cells transduced to overexpress human YTHDF2 were used validate overexpression 
efficiency as shown in supplementary information Figure S8b. Immunoblotting was performed 
with anti-YTHDF2 rabbit polyclonal antibody (MBL, RN123PW) and β-actin mouse 
monoclonal antibody (NOVUS, NB600-501). Secondary antibodies used were IRDye 800CW 
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Goat anti-Mouse IgG and IRDye 800CW Goat anti-Rabbit IgG antibodies (LI-COR). For 
intracellular staining, BM cells from wt and Ythdf2 KO mice were stained with HSC markers as 
above, then fixed with the Cytofix/Cytoperm kit (BD Biosciences) according to the 
manufacturer’s instructions. Fixed and permeabilized cells were immunostained with anti 
YTHDF2 antibody (MBL RN123PW), anti TAL1 antibody (Santacruz sc-393287), anti GATA2 
antibody (Santacruz sc-267), anti RUNX1 antibody (Santacruz sc-365644), anti STAT5 antibody 
(Santacruz sc-74442) and detected by Alexa-488 donkey anti-rabbit IgG antibody (Invitrogen). 
2.19     Single cell immunostaining. 
10,000 LSKs from wt and Ythdf2 KO mice were sorted onto Poly-L-lysine coating slides, 
which were placed in a moisture chamber and incubated at 4⁰C for 30 mins to allow cells settling 
onto the slides. Cells were fixed with chilled methanol at RT for 10 mins, blocked with universal 
blocking reagent (BioGenex) at RT for 30 mins, and stained with mouse TAL1 antibody (Santa 
Cruz, SC393287) or mouse IgG control (Abcam) at 4˚C overnight. Cells were then stained with 
Alexa Fluor 488 donkey anti-mouse IgG (Thermo Fisher Scientific) at 4˚C for 30 mins. Images 
were taken on a PerkinElmer Ultraview spinning disk system with Yokagawa CS-X1 disk. All 
emission was collected onto a C9100-23 Hamamatsu EM-CCD using Velocity software 
(PerkinElmer). For Z-stacks, the step size was set at 400nm. Staining intensity per image was 
quantified by ImageJ program. 
2.20     FISH in conjugation with fluorescent immunostaining. 
Sorted LSKs were spun onto microscope glass slide (Fisher Scientific Cat. No. 12-544-4) 
using a Cytospin™ 4 Cytocentrifuge at 800 rpm for 1 min with medium acceleration (Thermo 
Scientific, cat. no. A78300003), followed by an immediate immersion into 4% PFA (diluted 
from 16% (wt/vol) aqueous solution, Electron Microscopy Sciences, cat. no. 15710). Cells were 
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fixed at RT (25 ± 2 °C) for 30 mins. RNA in situ hybridization was performed using RNAscope 
multiplex fluorescent detection kit according to the manufacturer’s instructions (Advanced Cell 
Diagnostics) with a couple of modifications: Antigen retrieval was unnecessary, and digestion 
was performed with 1:15 diluted proteinase III solution for 10 mins at RT. RNAscope probes 
targeting mouse Tal1 and Gata2 were designed and produced by ACDbio. After the in situ 
hybridization was completed, slides were rinsed twice with PBST and directly processed with 
background blocking (Background buster solution, Innovex, cat. no. NB306) and primary 
antibody incubation. Anti-YTHDF2 (MBL, 1: 500) and anti-Dcp1α (Santa Cruz, SC100706, 
1:200) antibodies were diluted with antibody diluent reagent buffer (Life technologies, cat. no. 
003118) and incubated at 4°C overnight. Donkey anti- rabbit Alexa Fluor 488 (Invitrogen, 
1:500) and donkey anti-mouse Alexa Fluor 633 (Invitrogen, 1:500) were used for protein target 
multiplexing. 
2.21     Statistical analysis. 
Statistical analyses were done using Student's t test. The results are shown as the mean 
± s.e.m. 
2.22     Data availability.  
All sequencing data, including the m6A-seq, irCLIP-seq and RNA-seq datasets, are 
available through the Gene Expression Omnibus (GEO) under accession GSE107957.  









Chapter 3 : Ythdf2 KO leads to increase in phenotypic HSCs in primary mice 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
3.1       Examine the phenotype of Ythdf2 KO in mouse bone marrow 
In this chapter, I will examine the effect of Ythdf2 on hematopoiesis in the primary mice 
with the advent of cell surface markers and flow cytometry. To test this, we first crossed the 
Ythdf2 conditional knockout (KO) mice with a PolyI:C (pI:pC)-inducible Mx1-Cre mouse line 
(Kuhn, Schwenk, Aguet, & Rajewsky, 1995) to specifically reduce Ythdf2 expression in 
hematopoietic cells (hereafter Ythdf2 KO mice) (Figure 3.1A and B). Four weeks after pI:pC 
injections, we observed a significant increase in both frequency and absolute number of long-
term HSCs (Lin- Sca1+ cKit+ (LSK) CD34- Flk2-; LT-HSCs) and short-term HSCs (LSK CD34+ 
Flk2-; ST-HSCs), but not in multipotent progenitors (LSK CD34+ Flk2+; MPPs) in Ythdf2 KO 
mice compared to littermate wild type (wt) mice (Figure 3.1C to E). Although Ythdf2 KO led to 
increased BM cellularity, the absolute number of committed progenitors, including common 
myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), megakaryocyte-
erythrocyte progenitors (MEPs) and common lymphoid progenitors (CLPs), as well as mature 
lineage cells, erythrocytes, myeloid cells, B cells and T cells, showed no significant difference 








Figure 3.1 Ythdf2 KO leads to increase in phenotypic HSCs in mice. 
(A) Deletion of Ythdf2 in the HSPCs of Mx1-cre;Ythdf2f/f conditional KO (cKO) mice. (B) 
Western blot (left) and histogram (right) showing intracellular flow validation of KO Ythdf2 in 
mouse HSPCs. (C) Representative flow plots of HSPCs in BM from wt and Ythdf2 KO mice (n = 
5 for each group). (D and E) Frequency in total nucleated cells (TNC) (D) and absolute cell 
number (E) of HSPCs in BM from wt and Ythdf2 KO mice (n = 5 for each group). (F) Absolute 
number of BM TNC from wt and Ythdf2 KO mice (n= 5 for each group). (G and H) Absolute 
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number of committed progenitors (G) and lineage cells (H) in BM of wt and Ythdf2 KO mice (n 
= 5 for each group). Data shown as mean ± s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
3.2       Ythdf2 KO results in lower apoptotic rate in HSPCs without affecting cell cycle  
HSC quiescence has been well documented to play an essential role in maintaining LT-
HSC function and self-renewal capacity, disruption of which results in HSC exhaustion and 
places HSC under higher risk of tumorigenic mutagenesis (Jude, Gaudet, Speck, & Ernst, 2008; 
Kohli & Passegue, 2014; Nakamura-Ishizu, Takizawa, & Suda, 2014; Sanchez-Aguilera & 
Mendez-Ferrer, 2017). Given that we observed an increase in the number of phenotypic HSCs, 
we asked whether this is due to faster cell cycle, which may impair HSC quiescence and 
functionality. Cell cycle analysis revealed no discernible change of quiescence in HSCs or MPPs 
after Ythdf2 KO (Figure 3.2A). Notably, the percentage of apoptotic cells in Ythdf2 KO LT-, ST-





Figure 3.2 Ythdf2 KO results in lower apoptotic rate in HSPCs without affecting cell cycle. 
(A) Cell cycle analysis of HSPCs in wt (n = 3) and Ythdf2 KO (n = 4) mice. (B) Apoptosis 
analysis of BM HSPCs in wt and Ythdf2 KO mice (n = 5 for each group). Data shown as mean ± 
s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
3.3       Determine the splenic hematopoiesis in Ythdf2 KO mouse  
Adult splenic hematopoiesis, a type of extramedullary hematopoiesis, usually reflects 
pathological circumstances, such as immune response, within the organism (Kim, 2010). To 
further identify any potential HSC defects in Ythdf2 KO mice, we examined the number of 
HSCs, committed progenitors, and mature lineages in the spleen and found no significant 
differences between wt and Ythdf2 KO mice (Figure 3.3A-E). In summary, Ythdf2 KO in primary 





Figure 3.3 Splenic hematopoiesis is normal in Ythdf2 KO mice. 
(A) Images and weight of spleens from wt and Ythdf2 KO mice. (B to E) Absolute number of 
TNC (B), LSK CD48- CD150+ HSCs (C), committed progenitors (D) and lineage cells (E) in the 
























Chapter 4 : Ythdf2 KO expands functional HSCs in mice 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
4.1      Determine the frequency of reconstitution units from Ythdf2 KO mouse BM in     
primary transplantation recipients 
To determine whether Ythdf2 KO expands functional HSCs, we initially executed limited 
dilution, competitive repopulation unit assay (LDA) by transplanting 2 × 105, 7.5 × 104 or 2.5 × 
104 donor BM cells (CD45.2), together with 2 × 105 recipient BM cells derived from the ptprc 
mutant strain (CD45.1), into lethally irradiated recipient mice (Figure 4.1A). Consistent with an 
increased number of phenotypic HSCs in Ythdf2 KO mice, we found that competitive 
repopulating units (CRUs) increased 2.2-fold in Ythdf2 KO HSCs compared to controls (Figure 
4.1B). In the 2 × 105 group, compared to controls, we observed a significant increase in the 
overall repopulation rate from Ythdf2 KO donor cells at 16 weeks post transplantation (Figure 
4.1C). Moreover, recipients of Ythdf2 KO BM cells, compared to that of controls, exhibited 
markedly higher frequency and absolute number of donor derived LT-HSCs and ST-HSCs, but 
not MPPs in BM (Figure 4.1D and E). Furthermore, we found that donor derived committed 
progenitors and mature lineages in BM from transplantation recipients of mutant and wt cells 
showed no significant changes (Figure 4.1F and G). To exclude the possibility that homing 
ability may contribute to higher engraftment of Ythdf2 KO cells, we performed a short-term 
homing assay by transplanting 1×106 carboxyfluorescein diacetate succinimidyl ester (CFDA 
SE)-labelled BM cells from KO mice or their control littermates into lethally irradiated recipient 
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mice, and found no significant difference in their homing capacity between mutant and wt 
controls (Figure 4.1H).  
 
 
Figure 4.1 Ythdf2 KO HSCs expand in primary transplanted recipient mice. 
(A) Experimental scheme for limiting dilution transplantation assay (LDA) to determine the 
frequency of functional HSCs. (B) Primary LDA to determine the CRU frequency by ELDA 
(Extreme Limiting Dilution Analysis) at 16 weeks post transplantation (n = 10 per group). (C) 
Competitive reconstitution assay by transplanting 200K whole bone marrow (WBM) cells with 
200K rescue cells into irradiated recipients (n = 10 for each group). (D and E) Frequency in TNC 
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(D) and absolute cell number (E) of donor derived HSPCs in BM from transplantation recipient 
mice as (C) (n = 10 for each group). (Fand G) Absolute cell number of donor derived (CD45.2+) 
committed progenitors (F) and lineage cells (G) in BM from primary 200K BM transplantation 
recipient mice (n= 9-10 for each group). (H) Homing ability of wt and Ythdf2 KO cells was 
determined by transplanting 1×106 CFDA SE-labelled BM cells into lethally irradiated mice. 18 
hours later, BM was analyzed for homed events (n = 6 mice per group). Data shown as mean ± 
s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
4.2      Examine the frequency of LT-HSCs from Ythdf2 KO mouse BM in secondary 
transplantation recipients 
The gold standard test of HSC potential is the serial transplant assay. The most immature 
HSC should be able to sustain hematopoiesis throughout serial transplantation (Lemischka, 
Raulet, & Mulligan, 1986; Purton & Scadden, 2007; Rosendaal, Hodgson, & Bradley, 1979). 
Thus, to determine the long-term repopulation ability of HSCs from Ythdf2 KO mice, we 
conducted the secondary transplantation with BM cells derived from primary recipients. Notably, 
we found that compared to controls, CRUs from Ythdf2 KO cells revealed a 3.5-fold increase 
(Figure 4.2A) and exhibited no signs of leukemia in both BM and spleen at 16 weeks after 




Figure 4.2 Ythdf2 KO HSCs further expand in secondary transplant recipient mice without 
inducing leukemia. 
(A) Secondary LDA to determine the long-term CRU frequency by ELDA at 16 weeks after 
secondary transplantation (n = 10). (B to D) Absolute cell number of donor derived (CD45.2+) 
TNC (B), committed progenitors (C) and lineage cells (D) in the BM from secondary 200K 
transplantation recipient mice at 16 weeks after secondary transplantation (n= 7-10 for each 
group). (E to G) Absolute cell number of donor derived (CD45.2+) TNC (E), committed 
progenitors (F) and lineage cells (G) in the spleen from secondary 200K transplantation recipient 
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mice at 16 weeks after secondary transplantation (n= 7-10 for each group). Data shown as mean 
± s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
4.3      Test the long-term effect of Ythdf2 KO in primary mice under homeostasis condition 
Expansion of a clonal population of blood cells derived from a single HSC, known as 
clonal hematopoiesis, may endow higher risk of accumulating mutations that enhance HSC self-
renewal, leading to hematological malignancies with the passage of time (Bowman, Busque, & 
Levine, 2018). Thus, we questioned whether depletion of Ythdf2 would result in abnormal 
hematopoiesis in primary mice along with aging. To test this, we examined the stem cells, 
progenitor cells, and lineages in both BM and spleen at over 5 months post pI:pC injections 
(Figure 4.3A). Although we observed a modest increase in the number of LT-HSCs in BM from 
Ythdf2 KO mice compared to that of controls (Figure 4.3C), there were no discernible differences 
between Ythdf2 KO and control mice in total nucleated cell (TNC), progenitors and lineage cells 
from either BM or spleen (Figure 4.3B and D to J). These observations indicate that the long-
term effect of Ythdf2 KO in vivo neither skews lineage differentiation nor facilitates aberrant 
proliferation, which is in line with previous reports that Ythdf2 is not required for 
leukemogenesis (Z. Li et al., 2017a; Weng et al., 2018). To verify the frequency of functional 
HSCs in the BM at 5 months post pI:pC induction, we transplanted 7.5 × 104 BM cells from wt 
and Ythdf2 KO mice with competent cells into lethally irradiated recipients. We found that 
Ythdf2 KO led to significantly higher engraftment in recipients compared to wt controls, 
indicating that the number of functional, though not phenotypical, HSCs in 5-months post Ythdf2 
KO mice remained higher than that of control (Figure 4.3K). Taken together, these data reveal 







Figure 4.3 Ythdf2 KO has long-term effect on mouse HSC expansion in vivo without 
inducing lineage bias. 
(A) BM and spleen collected from wt and Ythdf2 KO mice were analyzed by flow cytometry at 
5-7 months post pI:pC inductions. (B to E) Absolute cell number of TNC (B), HSPCs (C), 
committed progenitors (D) and lineage cells (E) in the BM of wt and Ythdf2 KO mice at 5-7 
months post induction. (n = 4-7 mice per group). (F) The weight of spleens from wt and Ythdf2 
KO mice at 5-7 months post induction. (n = 4-7 mice per group). (G to J) Absolute cell number 
of TNC (G), LSK CD48- CD150+ HSCs (H), committed progenitors (I) and lineage cells (J) in 
the spleen of wt and Ythdf2 KO mice at 5-7 months post induction. (n = 4-7 mice per group). (K) 
5 months post pI:pC injection, 75k WBM from wt and Ythdf2 KO mice were transplanted with 
200K rescue cells into lethally irradiated recipients. Peripheral blood from transplantation 
recipients were analyzed every 4 weeks post transplantation to determine the donor derived 




















Chapter 5 : Ythdf2 regulates HSC self-renewal gene expression by m6A-mediated mRNA 
decay 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
5.1       Molecular characterization of m6A modification in mouse HSPCs 
In this chapter, I will explore the underlying mechanism of how Ythdf2 KO expands 
HSCs. According to the previous study on the function of YTHDF2, it is an m6A reader protein 
that recognizes m6A-marked mRNAs and promotes mRNA decay by recruiting to mRNA decay 
site (X. Wang et al., 2014). However, the transcriptome-wide map of m6A in mouse HSCs 
remains unknown. Thus, we first mapped the m6A methylome by methylated RNA 
immunoprecipitation combined with high-throughput sequencing (MeRIP-seq or m6A-seq) in 
LT-HSCs, ST-HSCs, and MPPs sorted from adult C57BL/6J mice (Dominissini et al., 2012; 
Meyer et al., 2012; Schwartz et al., 2013). m6A peaks were selected by identifying significantly 
enriched overlapping peaks from two independent replicates. Consistent with previous studies 
(Dominissini et al., 2012; Meyer et al., 2012), we found that m6A peaks were abundant in mRNA 
open reading frame (ORF), in 3’ untranslated regions (UTRs), and around the stop codon in all 
three HSPC populations (Figure 5.1A and B). Transcripts of moderately expressed genes were 
more likely to be methylated (Figure 5.1C). Intriguingly, we found that m6A modifications were 
enriched in the mRNAs of transcription factors, such as Gata2, Etv6, Stat5 and Tal1, which have 
been documented to be critical for HSC self-renewal and stem cell state maintenance (de Pater et 
al., 2013; Ebina & Rossi, 2015; Hock et al., 2004; Kato et al., 2005; Lim et al., 2012; Orkin & 
Zon, 2008; Reynaud et al., 2005; Z. Wang, Li, Tse, & Bunting, 2009), suggesting the m6A 
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modification could play critical roles in HSC regulation (Table 5.1). Given the accumulating 
evidence that m6A mRNA methylation regulates stem cell fate determination by facilitating the 
decay of mRNAs coding for transcription factors and genes in key signaling pathways involved 
in self-renewal and differentiation (Batista et al., 2014; Geula et al., 2015; H. B. Li et al., 2017; 
Z. Li et al., 2017a; Yoon et al., 2017a; C. Zhang et al., 2017a; B. S. Zhao, Wang, et al., 2017a), 
we next measured the mRNA degradation rates in LT-, ST-HSCs, and MPPs by monitoring 
mRNA levels after transcription inhibition with actinomycin D. We found that degradation rates 
of methylated mRNAs were significantly faster than unmethylated mRNAs in ST-HSCs, and 
MPPs but not LT-HSCs (Figure 5.1D).  
 
Gata2 Gfi1 Pbx1 
Lmo2 Etv6 Erg 
Runx1 Tal1 Hoxa9 
Meis1 Kmt2a Kmt2b 
Kmt2c Kmt2d Bmi1 
Sox4 Evi1 Stat3 
Stat5a Hoxb4 Zfx 
Foxo3 Foxp1  
 
Table 5.1 Key transcription factors critical for HSC self-renewal and maintenance are 




Figure 5.1 Molecular characterization of m6A modification in mouse HSPCs. 
(A) Metagene profiles depicting sequence coverage in windows surrounding the TSS (up) and 
stop codon (down). Coverage of m6A IP and control (input) fragments indicated in red and grey, 
respectively. (B) Pie chart presenting the fraction of m6A peaks in each of five transcript 
segments. (C) Fraction of genes in mouse HPSCs with m6A peaks in each of the segments as a 
function of expression level. (D) m6A-tagged and non-m6A-tagged mRNA degradation rates as 
determined by analysis of the expression level at 0 hour and 4 hours post actinomycin D 






5.2       Define Ythdf2 functionality by irCLIP-seq 
In this section, I will examine the mRNA targets of YTHDF2 in mouse multipotent 
hematopoietic precursor cell line HPC-7. In the previous section, I identified the transcriptome-
wide map of m6A in HSPCs and showed that mRNAs encoding transcription factors essential for 
stem cell self-renewal are enriched. Next, I asked whether YTHDF2 recognizes and mediates the 
degradation of these mRNAs. Thus, I performed infrared UV-crosslinking immunoprecipitation 
sequencing (irCLIP-seq) in HPC-7 cells (Figure 5.2A). irCLIP-seq, a derivation of CLIP assay, 
is a powerful technique for interrogating direct protein–RNA interactions with high efficiency 
and sensitivity (Zarnegar et al., 2016). I first repeated the published experiment (Zarnegar, 2016) 
as a pilot test and showed successful pulled down hnRNP-RNA complex as published data 
(Figure 5.2B). Though it would be best to profile the mRNA targets of YTHDF2 in mouse 
HSPCs, several commercial antibodies of YTHDF2 failed to pull down clear YTHDF2-RNA 
complex as visualized on nitrocellulose membrane (data not shown). Thus, to improve the 
efficiency of pulling down YTHDF2-RNA complex, I generated stable HPC-7 cell line 
expressing Flag-YTHDF2 driven by mammalian EF1α promoter. The efficiency of 
immunoprecipitation of YTHDF2 with anti-FLAG antibody from control or Flag-YTHDF2 
overexpression HPC-7 cell lysates was confirmed by western blot with anti-YTHDF2 antibody 
(Figure 5.2C). I then performed irCLIP-seq to determine the mRNA targets of YTHDF2 in HPC-
7 cells overexpressing Flag-YTHDF2 as indicated (Figure 5.2D and E). The results showed that 
YTHDF2 binding sites were enriched with the conserved m6A motif and exhibited the 
characteristic of m6A distribution features (Figure 5.2F and G). Consistent with the previous 
report that YTHDF2 function as a m6A reader protein (X. Wang et al., 2014), we found that 






Figure 5.2 Define Ythdf2 functionality by irCLIP-seq. 
(A) Schematic of irCLIP-seq workflow. (B) irCLIP membrane image showing IR800 labeled 
RNA-hnRNP complex isolated from Hela cells. (C) Immunoprecipitation of YTHDF2 in control 
or Flag-YTHDF2 overexpressed HPC-7 cells. (D) irCLIP membrane image showing IR800 
labeled RNA-Ythdf2 complex. Red box indicates the RNA-YTHDF2 complex collected for 
library construction. Samples without UV crosslinking serve as controls. (E) Venn diagram 
showing intersection genes identified in three independent Ythdf2 irCLIP-seq experiments. (F) 
YTHDF2-binding motif identified by MEME with all irCLIP peaks found in all three replicates. 
(G) Pie chart depicting the fraction of YTHDF2-binding peaks in each of five transcript 
segments. (H) Venn diagram showing overlap of Ythdf2 binding targets and m6A labeled 
mRNAs. 
 
5.3      YTHDF2 binds to m6A-labeled mRNAs encoding transcription factors essential for 
HSC self-renewal and results in their degradation 
To investigate the molecular mechanism underlying YTHDF2 regulation of HSC self-
renewal, I first performed Gene Ontology (GO) analysis of Ythdf2 target transcripts. This 
analysis revealed enrichment of genes related to hematopoietic or lymphoid organ development, 
suggesting the involvement of Ythdf2 in the regulation of hematopoiesis (Figure 5.3A). Notably, 
we found that Ythdf2 bound to transcription factor mRNAs, such as that of Tal1 and Gata2, on 
sites largely overlapping with m6A peaks (Figure 5.3B and C, Table 5.1). Then I tested the effect 
of Ythdf2 KO on RNA metabolism. I did not observe a significant difference in the total RNA 
mass in LSK Flk2- cells isolated from wt and Ythdf2 KO mice (Figure 5.3D). Though m6A 
modification constituted only 0.1-0.4% of adenosine nucleotide in mammal cells (B. S. Zhao, 
Roundtree, & He, 2017), we found that Ythdf2 KO led to increased level of m6A content in total 
RNA from BM Lin- cells, suggesting that Ythdf2 specifically regulates the stability of m6A-
marked mRNAs (Figure 5.3E). Consistently, qPCR analysis of total mRNA revealed increased 
levels of Tal1, Gata2, Runx1 and Stat5a (representative mRNAs with m6A modifications in 





Figure 5.3 YTHDF2 specifically binds to m6A-labeled mRNAs and results in degradation. 
(A) GO enrichment analysis of YTHDF2 targets from intersect genes of three YTHDF2 
irCLIPseq replicates. (B and C) Representative tracks of Tal1(B) and Gata2 (C) harboring m6A 
peaks and YTHDF2 irCLIP peaks. Coverage of m6A immunoprecipitation and input fragments 
indicated in red and grey, respectively. YTHDF2 irCLIP reads highlighted in yellow. (D) Total 
RNA was extracted from 15,000 sorted BM LSK Flk2- cells. (E) Quantification of m6A RNA 
methylation in wt and Ythdf2 KO Lin- cells (n = 6). (F) qPCR analysis of total mRNA of sorted 
LSK cells from wt and Ythdf2 KO mice. All Ct values were first normalized to Actb control (not 
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m6A-tagged) and the ratio (Ythdf2 KO over wt) was then calculated. (n = 3). Data shown as 
mean ± s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
Then I asked whether increased expression level of mRNAs encoding key transcription 
factors would result in higher protein levels in Yhtdf2 KO HSCs. To test this, I performed 
intracellular flow cytometry and found that Ythdf2 KO HSPCs exhibited significant increases in 
the intensities of m6A-labeled transcription factors involved in stem cell self-renewal, such as 
TAL1, GATA2, RUNX1 and STAT5, indicative of a suppressive role of Ythdf2 in HSC self-
renewal (Figure 5.4A). A previous study has shown that Ythdf2 regulates RNA metabolism 
through localizing the bound mRNAs to mRNA decay sites (X. Wang et al., 2014). To further 
explore the mechanism of Ythdf2 in regulating HSC self-renewal, we performed fluorescence in 
situ hybridization (FISH) of Tal1 mRNA and fluorescence immunostaining of YTHDF2 and 
DCP1a, a marker of mRNA decay sites (Kedersha & Anderson, 2007; Sheth & Parker, 2003), 
and analyzed their relative spatial distribution in sorted wt and Ythdf2 KO HSPCs. Co-
localization of Tal1 mRNA, Dcp1a and Ythdf2 was observed in wt cells, while substantially 
reduced in Ythdf2 KO controls (Figure 5.4B and C). Furthermore, a similar observation was 
confirmed by co-staining Gata2 mRNA FISH with Ythdf2 and Dcp1a in wt or Ythdf2 KO 
HSPCs (Figure 5.4D and E). To determine whether the increased transcription factors, such as 
Tal1, expression accounted for the HSC expansion in Ythdf2 KO mice, we performed rescue 
experiments using short hairpin (sh) RNA-mediated Tal1 KD in wt and Ythdf2 KO LSK cells, 
followed by transplantation into lethally irradiated recipients. Depletion of Tal1 in HSPCs 
significantly impaired the reconstitution capacity of wt cells as reported previously (Lacombe et 
al., 2010) and also rescued in partial the increased engraftment of Ythdf2 KO cells (Figure 5.4F). 
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Overall, these data indicate that Ythdf2 regulates HSC self-renewal by enabling the degradation 






Figure 5.4 YTHDF2 regulates HSC self-renewal by promoting m6A-marked mRNA decay. 
(A) Quantification (right) and histogram (left) showing intracellular flow validation of increased 
expression of TAL1, GATA2, RUNX1 and STAT5 in Ythdf2 KO LT-HSCs comparing to wt LT-
HSCs (n = 3 mice per group). (B) Fluorescence in situ hybridization of Tal1 mRNA (red) and 
fluorescence immunostaining of DCP1a (P-body marker) (magenta), YTHDF2 (green) in wt and 
Ythdf2 KO HSPCs. Arrows indicate colocalized staining. Scale bars, 5 μm. (C) Quantification of 
Tal1 mRNA and DCP1a co-localization in sorted LSK cells from wt and Ythdf2 KO mice. 
Percentage indicates the average frequency of the Tal1 mRNA that colocalized with DCP1a over 
total Tal1 mRNA level in each LSK cells (n = 9–17). (D) Fluorescence in situ hybridization of 
Gata2 mRNA (red) and fluorescence immunostaining of Dcp1a (P-body marker) (magenta), 
Ythdf2 (green) in wt and Ythdf2 KO HSPCs. Arrows indicate co-localized staining. Scale bars, 5 
μm. (E) Quantification of Gata2 mRNA and DCP1a colocalization in sorted LSK cells from wt 
and Ythdf2 KO mice. Percentage indicates the average frequency of the Gata2 mRNA that co-
localized with DCP1a over total Gata2 mRNA level in each LSK cells (n = 12-20). (F) 
Percentage of GFP+ cells in the CD45+ population at 4 weeks post transplantation (n = 10). Data 


















Chapter 6 : Dissecting the role of Ythdf2 in human UCB HSPCs by m6A-seq and RNA-seq 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
The limited number of HSCs in a single human umbilical cord blood unit has been an 
obstacle for clinical applications, such as HSC transplantation (Walasek et al., 2012). Our 
observation that Ythdf2 KO resulted in an increase of phenotypic and functional mouse HSCs 
prompted us to test whether YTHDF2 KD could facilitate human UCB HSC expansion. We first 
performed m6A-seq with CD34+ cells isolated from 3 individual hUCB samples (Figure 6.1A). 
m6A modifications predominantly occurred in mRNAs (~95%), preferential in mRNA ORF 
regions, 3’UTRs, and near the stop codon, as expected (~90%) (Figure 6.1B-D). We further 
compared m6A landscapes in mouse and hUCB HSPCs and found that 2,239 genes were 
commonly m6A tagged (Figure 6.1E). These commonly m6A-tagged transcripts were enriched 
for genes related to hematopoiesis and stem cell maintenance (Figure 6.1F). Due to the 
enrichment of m6A labeling in the mRNAs of transcription factors responsible for mouse HSC 
self-renewal, we next characterized the m6A-marked transcription factor transcripts in hUCB 
CD34+ cells by performing GO term analysis. Among the 722 identified m6A-labeled 
transcription factor mRNAs, major GO terms were related to cell fate commitment and stem cell 
maintenance (Figure 6.1G). For example, HOXB4, overexpression of which has been reported to 
expand human and mouse HSCs ex vivo (Amsellem et al., 2003; Antonchuk et al., 2002), was 
marked by m6A in hUCB CD34+ cells (Figure 6.1H). Other transcription factors required for 
HSC self-renewal and critical to induce HSCs from other cell types (Ebina & Rossi, 2015; 
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Galan-Caridad et al., 2007), such as Zfx, RUNX1 and FOSB, were also m6A-tagged in hUCB 








Figure 6.1 Determine the RNA methylome in human UCB HSPCs by m6A-seq. 
(A) Venn diagram showing intersection genes identified in three independent m6A-seq 
experiments, using three independent cord blood samples. (B) Percentage of mRNAs and 
noncoding RNAs containing m6A peaks. (C) Metagene profiles depicting sequence coverage in 
windows surrounding the TSS (left) and stop codon (right). Coverage of m6A IP and control 
(input) fragments indicated in red and grey, respectively. (D) Pie chart presenting the fraction of 
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m6A peaks in each of five non-overlapping transcript segments. (E) Venn diagram showing 
shared and unique m6A-tagged genes in mouse and hUCB HSPCs. (F) GO enrichment analysis 
of m6A-tagged transcripts shared in both mouse and hUCB HSPCs. (G) GO enrichment analysis 
of the transcription factors harboring m6A modifications in hUCB CD34+ cells. (H) 
Representative tracks of HOXB4 harboring m6A peaks. Color codes are the same as in (C). 
 
To further dissect the role of YTHDF2 in hUCB HSPCs, we performed RNA-seq with control or 
YTHDF2 KD hUCB CD34+ cells (Figure 6.2A). The efficiency of knockdown YTHDF2 was 
verified at both protein and RNA level by western blot and RNA-seq, respectively (Figure 6.2B 
and C). Remarkably, transcripts marked by m6A, including HOXB4 and other HSC self-renewal 
related transcription factors, showed significant increases of input mRNA reads in the YTHDF2 
KD cells compared to the control, without noticeable changes for non-m6A labelled genes 
(Figure 6.2D-F and Figure 6.3). These results support the role of YTHDF2 in regulating hUCB 




Figure 6.2 Dissect the mechanism of YTHDF2 regulating m6A-labeled mRNAs by RNA-
seq. 
(A) Lentivirus mediated YTHDF2 KD in hUCB CD34+ HSPCs for RNA-seq. (B) Western 
blotting of YTHDF2 (up) and β-Actin (down) in sorted GFP+ control and YTHDF2 KD hUCB 
cells, showing knockdown efficiency of YTHDF2. (C) Expression level (left) and representative 
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track plot (right) of YTHDF2 from RNA-seq analysis of control and YTHDF2 KD hUCB CD34+ 
cells, showing knockdown efficiency of YTHDF2. (D) Cumulative distribution of log2 (fold 
change) for m6A-marked genes (purple line) and non-m6A-marked genes (black line) with 
control and YTHDF2 KD hUCB CD34+ cells. (E) Representative coverage plots from the RNA-
seq analysis, showing increased reads of m6A-tagged gene HOXB4 but not a non-m6A-tagged 
gene ACTB in YTHDF2 KD compared with control hUCB CD34+ cells. RPKM from RNA-seq 





Figure 6.3 Track files of m6A-seq and RNA-seq for genes presented in Figure 6.2. 
Representative track plots of indicated transcription factors harboring m6A peaks (up) and their 
representative coverage plots from the RNA-seq analysis (bottom). 
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Chapter 7 : Expansion of human UCB HSCs by YTHDF2 Knockdown 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
7.1       YTHDF2 KD facilitates expansion of human cord blood HSCs ex vivo. 
In this chapter, I will explore whether suppression of YTHDF2 can expand human HSCs. 
I next performed shRNA-induced YTHDF2 KD in hUCB HSPCs followed by expansion ex vivo 
for 7 days. After 7 days ex vivo culture, lentiviral mediated KD of YTHDF2 resulted in an 
average 14.3-fold and 13.6-fold increase, respectively, in the frequency and absolute number of 
CD34+ CD38- CD45RA- EPCR+ phenotypic HSCs (Figure 7.1 A-C). Next I sorted out the 
lentivirus infected GFP+ cells from control or YTHDF2 KD groups by FACS and performed the 
colony-forming cell (CFC) assay which measures progenitor cells in a given population using 
semisolid agar- or well-defined methylcellulose-based culture media, which are commercially 
available (Purton & Scadden, 2007). Two weeks post culture, the number of colonies derived 
from YTHDF2 KD cells exhibited a 5.1-fold increase in CFUs relative to control cells. Among 
different CFU categories, more dramatic increase was seen in the most primitive CFU-
granulocyte erythrocyte monocyte megakaryocyte (GEMM) colony type and burst forming unit-
erythroid (BFU-E), reflecting higher expression level of key transcription factors for 
hematopoiesis, such as TAL1, in YTHDF2 KD hUCB cells (Figure 7.1D and E). Interestingly, the 
apoptotic rate was significantly reduced in YTHDF2 KD hUCB HSPCs compared to control 
cells, similar to the trend of HSCs in Ythdf2 KO mouse (Figure 7.1F). We next compared the 
effect of overexpression of YTHDF2 on HSPC function. The efficiency of YTHDF2 
overexpression was verified by western blot (Figure 7.1G). Overexpression of YTHDF2 reduced 
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clonogenic potential of hUCB HSPCs by 2.2-fold, confirming that YTHDF2 negatively regulates 






Figure 7.1 YTHDF2 KD facilitates expansion of human cord blood HSCs ex vivo. 
(A) Representative flow plots of GFP+ CD34+ CD38- CD45RA- EPCR+ HSCs in control and 
YTHDF2 KD hUCB cells post 7 days culture. (B and C) Fold change of frequency (B) and 
absolute number (C) of indicated cells in YTHDF2 KD over control cells after 7 days culture. 
(D) CFU output from transduced CD34+ CD38− hUCB cells and images of CFU the granulocyte-
erythrocyte-monocyte-megakaryocytes (GEMMs) (scale bar, 200 μm). (E) Images of burst 
forming unit-erythroid (BFU-E) (left) and colony-forming unit-granulocyte/macrophage (CFU-
GM) (right) from 7 days cultured control or YTHDF2 KD hUCB cells (scale bar, 200 μm). 
Three independent cord blood samples were used, and this was repeated twice for (A) to (E). (F) 
Apoptosis analysis of CD34+ CD38- cells in 7-day cultures of transduced CD34+ hUCB cells by 
Annexin V staining (n = 3 independent CB samples). (G) Confirmation of YTHDF2 protein 
knockdown and overexpression in transduced Hela cells. (H) CFU production by YTHDF2 
overexpression (OE) and control transduced CD34+ CD38- CB from day 10 cultures (n = 3 
independent human samples). Data shown as mean ± SEM. Unpaired t-test. n.s. nonsignificant 
 
7.2       YTHDF2 KD facilitates expansion of human cord blood functional LT-HSCs 
To determine whether YTHDF2 KD can expand human HSCs in vivo, we performed 
LDA by transplanting GFP+ cells sorted from hUCB CD34+ cells infected with control and 
YTHDF2 shRNA at day 4 post infection (Figure 7.2A). For hUCB HSC primary LDA assay, in 
brief, CD34+ cells were enriched as described above and transduced with human YTHDF2 
shRNA or control shRNA at 50 MOI. Media were changed at 24 hours post infection. Equal 
number of GFP+ cells were sorted out from control or YTHDF2 KD cells on 3 days post infection 
and cultured overnight. Three doses, 50K, 20K and 10K, of sorted GFP+ cells were transplanted 
into sublethally irradiated (3.25Gy) NSG mice, respectively. At 10 weeks post transplantation, 
we analyzed BM cells from recipient NOD/SCID Il2rgnull (NSG) mice and measured the 
functional HSC frequency after in vivo expansion. Notably, compared to control group, 
recipients of YTHDF2 KD cells displayed a 9-fold increase in human hematopoietic cell 
(hCD45+ GFP+) engraftment in BM (Figure 7.2B and C, Table 7.1). YTHDF2 KD significantly 
increased the percentage of myeloid, megakaryocyte and erythrocyte in the BM of primary 
recipients without changes in the proportions of each lineage (Figure 7.2E-G). Accordingly, I 
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found that the HSC frequency in YTHDF2 KD cells was increased 4.4-fold relative to that in 






Figure 7.2 YTHDF2 KD hUCB HSCs expand in primary transplanted recipient mice. 
(A) Experimental scheme for measuring frequency of HSCs after in vivo expansion. (B) 
Representative flow plots of hCD45+ GFP+ reconstitution from primary recipient mice receiving 
the highest two cell doses. hCD45, human CD45 (C) hCD45+ GFP+ engraftment in BM from the 
primary recipient mice that received the highest two doses (n = 8). (D) HSC frequency 
determined by primary LDA. Dashed lines indicate 95% confidence intervals. (E) Representative 
flow plots of hCD45+ GFP+ monocyte, megakaryocyte (MK cell), B cell and erythrocyte in 
primary NSG recipient BM. (F and G) Percentage of lineage cells in hCD45+ GFP+ (F) and in 
total CD45+ (G) BM cells from primary NSG recipients at 10 weeks post transplantation (n = 13-
15). Data shown as mean ± s.e.m. Unpaired t-test. n.s., nonsignificant. 
 
Next, I confirmed the long-term capability of YTHDF2 KD hUCB HSCs to be 
reconstituted and to undergo self-renewal; 12 weeks after transplantation of BM from primary 
recipients into sublethally irradiated secondary NSG recipient mice, human hematopoietic cell 
chimerism in BM were higher in the YTHDF2 KD group, as compared to that in the control 
group (Figure 7.3A, B and D). CRUs from YTHDF2 KD cells revealed an 8-fold increase 
relative to that in control cells (Figure 7.3C and Table 7.1). These data demonstrate that YTHDF2 
KD remarkably facilitates the expansion of both phenotypic and long-term functional hUCB 




Figure 7.3 YTHDF2 KD HSCs further expand in secondary transplanted recipient mice. 
(A) Representative flow plots of hCD45+ GFP+ reconstitution from secondary recipient mice 
receiving the highest two cell doses. (B) hCD45+ GFP+ engraftment in BM from secondary 
recipient mice that received the highest two doses (n = 6). (C) HSC frequency determined by 
secondary LDA. Dashed lines indicate 95% confidence intervals. (D) Summary of human donor 
derived lineage chimerisms in total CD45+ BM cells from secondary NSG recipients at 12 weeks 
post transplantation (n = 6). Data shown as mean ± s.e.m. Unpaired t-test. n.s., nonsignificant. 
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Chapter 8 : Discussion 
Sections of chapters 2-8 have previously been published and are adapted and reprinted here with 
permission, alongside new, never-before published material.  Li, Z., Qian, P., Shao, W. Shi, H., 
He, X.C., Gogol, M.,. . . Li, L. (2018). Suppression of m(6)A reader Ythdf2 promotes 
hematopoietic stem cell expansion. Cell Res, 28(9), 904-917. 
 
Although recent studies shed light on the biological functions of mRNA m6A 
modifications (Alarcon, Goodarzi, et al., 2015; Alarcon, Lee, Goodarzi, Halberg, & Tavazoie, 
2015; Bertero et al., 2018; T. Chen et al., 2015; Fustin et al., 2013; Haussmann et al., 2016; 
Huang et al., 2018; Ivanova et al., 2017; Lence et al., 2016; N. Liu et al., 2015; Pendleton et al., 
2017a; Schwartz, Bernstein, et al., 2014; Shi et al., 2017a; Slobodin et al., 2017; Wojtas et al., 
2017; Xiao et al., 2016; S. Zhang et al., 2017; Zheng et al., 2013; J. Zhou et al., 2015), our work 
identifies Ythdf2 as an important regulator of human and mouse HSC self-renewal by coupling 
the post-transcriptional m6A modification to the degradation of mRNAs encoding key 
transcription factors for self-renewal. Repression of Ythdf2 in mouse HSPCs and hUCB HSCs 
leads to increased expression of multiple key TFs critical for self-renewal, thereby facilitating ex 
vivo expansion of both phenotypic and functional HSCs without noticeable lineage bias and 
leukemia potential. In addition, stem cell niches, to some extent, may contribute to Ythdf2 
suppression-mediated mouse HSC expansion as Mx1-cre can be activated in mesenchyme 
stromal cells (Joseph et al., 2013). It would be intriguing to study the function of Ythdf2 on 
MSCs and how repression of Ythdf2 in both HSCs and MSCs may synergistically expand HSCs 
in vivo. Our ex vivo expansion of human HSCs showed that suppression of Ythdf2 in HSCs is 
able to expand HSCs, as seen in this study.  
Given the broad and complicated impact of m6A writer complex Mettl3 and Mettl14 on 
mRNA splicing, translation, and pri-miRNA processing (Alarcon, Lee, et al., 2015; Barbieri et 
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al., 2017a; N. Liu et al., 2015), Mettl3 or Mettl14 depletion results in distinct outcomes in normal 
stem cells and leukemia. Recent studies have demonstrated that Mettl3 and Mettl14 play essential 
roles in leukemia development and leukemia stem cell maintenance (Barbieri et al., 2017a; Vu et 
al., 2017a; Weng et al., 2018). In contrast, Ythdf2 is mainly involved in m6A-mediated mRNA 
decay by which stem cells are shown to be influenced (Batista et al., 2014; Shlush et al., 2014; 
Yoon et al., 2017a; C. Zhang et al., 2017a). Therefore, manipulating Ythdf2 would extend the 
half-life of specific m6A-marked mRNAs encoding TFs critical for stem cell self-renewal 
without affecting other aspects of mRNA processing. In line with this, our data clearly show that 
Ythdf2 depletion in HSCs neither skews the lineage commitment nor induces hematological 
malignancies, reducing the risk of leukemogenesis with expanded HSCs. Furthermore, stem cell 
self-renewal is a complex process involving promoting cell division, inhibiting apoptosis, 
preventing differentiation, and stemness retention (S. He, Nakada, & Morrison, 2009). Our 
observation that Ythdf2-deficient HSCs exhibited lower apoptotic rates accounts for at least one 
aspect of stem cell self-renewal mechanism. We believe that stemness retention is another 
mechanism underlying the Ythdf2-mediated HSC expansion. 
A major limitation in using hUCB HSC transplantation is the insufficient number of 
HSCs in one hUCB unit. Albeit previous studies have revealed that Dlk1, SR1, Musashi2 and 
UM171 can expand hUCB HSCs by targeting Notch, AHR signaling or other unknown pathway 
(Boitano et al., 2010; Chou, Flygare, & Lodish, 2013; Fares et al., 2014; Rentas et al., 2016), our 
work provides a novel and potent way to target multiple key TFs critical for HSC self-renewal 
and to enhance the expansion of  HSCs. Reducing Ythdf2 level and function during in vitro 
culture via small chemicals or AAV-mediated KD allows the Ythdf2 level and function to restore 
after transplantation in vivo, and thus not affect normal HSC maintenance and function in human 
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patients. Furthermore, we envision that combining our method with previous ones may facilitate 
the expansion of not only human HSCs, but also other stem cells, rendering a potential approach 
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